KUNMING, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo
Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company") (Amex:
KUN), which is engaged in the research, development, manufacture, and
marketing of pharmaceutical, nutritional supplement and cosmetic products
in the People's Republic of China ("PRC"), today announced that Lei Lan,
Executive Director of Sales, and Qionghua Gao, Chief Financial Officer, are
scheduled to present at the Roth Capital Partners 2007 New York Conference.
    The Roth Capital Partners 2007 New York Conference is a two-day event
featuring presentations and one-on-one meetings with more than 230 small
and microcap growth companies in a variety of industries.
     Date:                Thursday, September 6, 2007
     Time:                12:00 p.m. EDT
     Venue:               The Westin New York at Times Square
     Live webcast:        http://www.wsw.com/webcast/roth13/csheng/
    A replay of the webcast will be available for 90 days beginning the
afternoon of the presentation.
    About China Shenghuo Pharmaceutical Holdings, Inc.
    Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China
Shenghuo" or "the Company") is a leading specialty pharmaceutical company
that focuses on the research, development, production and marketing of
Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo
Pharmaceutical (Group) Co., Ltd ("Kunming Shenghuo"), it owns thirty-one
SFDA (State Food and Drug Association)-approved medicines, including the
flagship product Xuesaitong Soft Capsules, which has already been listed in
the Insurance Catalogue. At present, Shenghuo incorporates a sales network
of agencies and representatives throughout China, which markets
Sanchi-based traditional Chinese medicine into 1,650 hospitals and 1,500
drug stores as prescription and OTC drugs primarily for the treatment of
cardiovascular, cerebrovascular and peptic ulcer disease. The Company also
exports medicinal products to Asian countries such as Indonesia, Russia and
Kyrgyzstan.
    Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995: This press release contains certain "forward-looking
statements," as defined in the United States Private Securities Litigation
Reform Act of 1995, that involve a number of risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and the
actual results and future events could differ materially from management's
current expectations. Such factors include, but are not limited to, the
company's reliance on one supplier for Sanchi, ability to develop and
market new products, ability to establish and maintain a strong brand,
continued maintenance of certificates, permits and licenses required to
conduct business in China, protection of company's intellectual property
rights, market acceptance of the company's products, changes in the laws of
the People's Republic of China that affect the company's operations, any
recurrence of severe acute respiratory syndrome or avian flu, the company's
ability to obtain all necessary government certifications and/or licenses
to conduct the company's business, development of a public trading market
for the company's securities, cost of complying with current and future
governmental regulations and the impact of any changes in the regulations
on the company's operations and other factors detailed from time to time in
the Company's filings with the United States Securities and Exchange
Commission and other regulatory authorities. The company undertakes no
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
    For more information, please contact:

     Ms. Gao Qionghua, CFO
     China Shenghuo Pharmaceutical Holdings, Inc.
     Tel:   +86-871-7282608
     Email: qionghua_kmsh@163.com

     Crocker Coulson, President
     CCG Elite Investor Relations
     Tel:   +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com

Link to this page: